Heute ein Plus von 48% nach einer Leidenszeit seit Juni letzten Jahres:

Organigram mit guten Q-Zahlen. Der Gewinn von 0,0 übertrifft die Verlustschätzungen von -0,02$ /Aktie der Analysten.
Der Umsatz legt mit 25,15 Mio. um 102,2% im Vorjahresvergleich zu, und liegt damit um 10,24 Mio. über den Analystenschätzungen. Sensationell in diesem schwierigen Umfeld der Cannabisbranche in Kanada.

Ich behaupte ja schon lange, dass Organigram das beste Management aller kanadischen Pot-Stocks hat. Die hatten nie verrückte Expansionspläne, sind immer bescheiden geblieben, waren aber die ersten die über mehrere Quartale Gewinne gemacht haben, und machen auch heute keine Verluste.

Natürlich hat Organigram bei weitem keine so starke Bilanz wie Canpy Growth oder Cronos. Doch dafür haben sie eine akzeptable Bilanz, und als einzige haben sie ein gesundes operatives Geschäft. 

Auffrischung der Kaufempfehlung von mir - aber nur mit einer kleinen spekulativen Position.

Guter Artikel bei fool.com: 
https://www.fool.com/investing/2020/02/18/where-will-organigram-holdings-be-in-10-years.aspx

Die letze Buy Empfehlung habe ich bei 1,58 beendet.

Im letzten Mai war die Aktie noch bis übe 7€ wert. Wir sind jetzt in der Nähe des Tiefs von 2017. In diesem Bereich sollte der Absturz ein Ende finden. 

Organigram hat eine solide Finanzierung, niedrige Produktionskosten, einen funktionierenden Vertrieb mit treuen Stammkunden, einen guten Ruf in der Szene, und steht nahe der Gewinnschwelle. Kein Vergleich mit Aurora. 

Erstes Kursziel 1,80 - dann sehen wir weiter.

MONCTON, Canada (AP) _ OrganiGram Holdings Inc. (OGI) on Tuesday reported a loss of $64.8 million in its fiscal third quarter.

The Moncton, Canada-based company said it had a loss of 37 cents per share. Earnings, adjusted for non-recurring costs and asset impairment costs, came to less than 1 cent on a per-share basis.

The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 2 cents per share.

The cannabis producer posted revenue of $13 million in the period, which did not meet Street forecasts. Six analysts surveyed by Zacks expected $16.4 million.

The company's shares closed at $1.52. A year ago, they were trading at $6.43.
https://www.bigrapidsnews.com/business/article/OrganiGram-Fiscal-3Q-Earnings-Snapshot-15422632.php

Dump Sundial for this Canadian marijuana stock

My suggestion to the cannabis investment community is simple: Dump this zero and find yourself a Canadian pot stock hero, like OrganiGram Holdings (NASDAQ:OGI).

OrganiGram is a New Brunswick-based producer that's operating only one facility (Moncton). Having a single production and processing site makes it easy for OrganiGram to tweak its output and expenses to match prevailing market conditions. Should future demand merit a full expansion of the Moncton facility, OrganiGram could produce north of 110,000 kilos of weed per year.

The facility is set up to drive efficiency. Cultivation rooms employ three tiers of growing to maximize yield and drive down per-gram production costs. OrganiGram also acquired fully automated equipment capable of producing up to 4 million kilos of chocolate-infused edibles each year. Further, it developed a proprietary powder that can be added to beverages to expedite the time it takes for cannabinoids to take effect. OrganiGram is built to see the retail cannabis market drive its operating margins above the industry average over the long run.

If you need even more evidence that OrganiGram is the better value, how about this: In the current year, Sundial is expected to generate $63.5 million in sales. By comparison, OrganiGram's full-year revenue should top $106 million, with the company having an outside shot at turning the corner to profitability.

OrganiGram's market cap of $542 million is less than a third that of Sundial, but it's a much more well-rounded cannabis company. Do yourself (and your wallet) a favor and don't get lured in by the baseless hype surrounding Sundial Growers.

This article represents the opinion of the writer, who may disagree with the "official" recommendation position of a Motley Fool premium advisory service. We're motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.